GlassScriptPhysician profile
Yousuf Khan
NPI 1104116391
$1,309.85
in general payments reported to CMS, 2019-2025
20 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2021: $81.62 · 2023: $143 · 2024: $320 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $426.70 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $116.00 | 2019-2024 | Mounjaro |
| Valeritas, INC. | $110.58 | 2019 | |
| Medtronic, INC. | $106.25 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $90.59 | 2021-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $66.55 | 2019-2024 | |
| Dexcom, INC. | $58.44 | 2019-2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $46.27 | 2019-2025 | Omnipod |
| Medtronic Minimed, INC. | $45.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $35.71 | 2023-2024 | |
| Corcept Therapeutics | $28.88 | 2019 | |
| Radius Health, INC. | $26.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.12 | 2024 | |
| Amgen INC. | $23.31 | 2019 | |
| Antares Pharma, INC. | $22.81 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $21.01 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.43 | 2023 | Recorlev |
| Sequel Med Tech, LLC | $14.79 | 2025 | Twiist |
| Vivus LLC | $13.02 | 2019 | |
| Ibsa Pharma INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yousuf Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.